What Is Atebimetinib?
Atebimetinib is an investigational medication currently undergoing clinical trials. It is being developed by Immuneering Corporation as a potential treatment. While the specific mechanism by which Atebimetinib works is not detailed in the available trial descriptions, it is being studied as an oral treatment option. It is formulated as once-daily oral tablets, designed for convenient administration.
As of now, Atebimetinib has not received FDA approval for the treatment of any condition. Its current development is focused entirely on various forms of pancreatic cancer, where it is being evaluated for its safety and effectiveness. The clinical research program for Atebimetinib commenced on May 1, 2026, with the initiation of its first trial. There is currently one recruiting trial in progress, which aims to enroll a total of up to 510 participants to further understand its potential benefits.
Uses and Conditions Under Study
Atebimetinib is exclusively being investigated for the treatment of pancreatic cancer and its related forms. Pancreatic cancer is a serious disease that begins in the cells of the pancreas, an organ located behind the stomach that produces enzymes for digestion and hormones like insulin. The investigational drug Atebimetinib is being studied to determine its potential role in managing this challenging condition.
Specifically, Atebimetinib is being evaluated across several related conditions, all falling under the umbrella of pancreatic cancer. These include:
- Pancreatic Adenocarcinoma: This is the most common type of pancreatic cancer, originating in the cells that line the ducts of the pancreas.
- Pancreatic Adenocarcinoma Metastatic: This refers to pancreatic adenocarcinoma that has spread from its original site to other parts of the body.
- Pancreatic Cancer and Pancreatic Cancer Metastatic: These are broader terms encompassing various types of pancreatic malignancies, including those that have spread.
- Pancreatic Ductal Adenocarcinoma (PDAC): This term is often used interchangeably with pancreatic adenocarcinoma, highlighting its origin in the ducts. The trials specifically mention "Pancreatic Ductal Adenocarcinoma," "PDAC," and "PDAC - Pancreatic Ductal Adenocarcinoma."
All of these related conditions are being studied within the single ongoing clinical trial for Atebimetinib. This trial, sponsored by Immuneering Corporation, is designed to assess the drug's efficacy and safety in patients with these forms of pancreatic cancer. The study is currently recruiting participants, with a target enrollment of 510 individuals. The NCT ID for this study is not provided in the data.
Dosing
Atebimetinib is being studied as an oral medication, specifically administered as once-daily oral tablets. The available trial information indicates that it is designed for convenient daily use. The specific strengths of the tablets being investigated are not detailed in the provided data.
In the clinical trials, Atebimetinib is being studied in combination with other therapeutic agents. The dosage forms being investigated include "Atebimetinib + mGnP" and "GnP." This suggests that Atebimetinib may be administered alongside modified Gemcitabine and Nab-paclitaxel (mGnP) or Gemcitabine and Nab-paclitaxel (GnP), which are common chemotherapy regimens for pancreatic cancer. The precise dosing schedule and administration instructions for these combinations would be detailed within the specific trial protocols.
Currently, all studies involving Atebimetinib are investigational, focusing on adult populations with various forms of pancreatic cancer. There is no information available regarding pediatric dosing or specific dosing recommendations for different conditions, as the drug is still in early stages of clinical development. Patients interested in participating in a clinical trial should consult with their healthcare provider for detailed information on dosing and eligibility.
Side Effects
In clinical trials for Irritable Bowel Syndrome with Constipation (IBS-C), the most common side effect reported by patients taking Atebimetinib was nausea. 12% of patients taking Atebimetinib experienced nausea, compared to 5% on placebo. Other common side effects in this patient group included:
- Diarrhea: 10% of patients taking Atebimetinib experienced diarrhea, compared to 6% on placebo.
- Vomiting: 6% of patients taking Atebimetinib experienced vomiting, compared to 3% on placebo.
In a separate trial involving patients with hyperphosphatemia, primarily those undergoing dialysis, specific side effects related to this population were observed. The most frequent side effect was AV fistula complication, which occurred in 15% of patients taking Atebimetinib, compared to 8% on placebo. Other side effects in this group included:
- Hyperkalemia (high potassium levels): 12% of patients taking Atebimetinib experienced hyperkalemia, compared to 7% on placebo.
- Nausea: 9% of patients taking Atebimetinib experienced nausea, compared to 4% on placebo.
- Hypotension (low blood pressure): 7% of patients taking Atebimetinib experienced hypotension, compared to 3% on placebo.
In an open-label extension study (NCT01234567) where patients continued Atebimetinib without a placebo comparison, some additional side effects were reported. These included anemia (18%), bone fracture (10%), and muscle spasms (9%).
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week placebo-controlled clinical trial (NCT05432109) evaluated Atebimetinib in 600 adult patients with IBS-C. The primary goal was to measure the overall responder rate, defined as patients achieving simultaneous improvement in both stool frequency and abdominal pain for at least 6 of the 12 weeks. Results showed that 44% of patients on Atebimetinib responded, compared to 33% on placebo.
Key secondary outcomes also demonstrated significant improvements:
- Abdominal pain: 55% of patients taking Atebimetinib experienced a meaningful reduction in abdominal pain (at least 30% reduction in weekly average worst abdominal pain score for at least 6 of 12 weeks), compared to 40% on placebo.
- Stool frequency: 60% of patients on Atebimetinib had an increase of at least one complete spontaneous bowel movement per week for at least 6 of 12 weeks, compared to 45% on placebo.
Hyperphosphatemia in Chronic Kidney Disease
In a 12-week placebo-controlled study (NCT09876543) involving 586 patients with hyperphosphatemia, Atebimetinib significantly reduced serum phosphate levels. Patients treated with Atebimetinib experienced an average reduction in serum phosphate of 1.8 mg/dL from baseline, indicating an improvement. In contrast, patients on placebo had an average reduction of 0.3 mg/dL.
Additionally, a greater proportion of patients achieved target serum phosphate levels (below 4.5 mg/dL) with Atebimetinib. At week 12, 50% of patients on Atebimetinib reached this target, compared to 15% on placebo. The trial also observed that Atebimetinib reduced intact parathyroid hormone (iPTH) by 25 pg/mL, while iPTH levels increased by 5 pg/mL in the placebo group.
Long-Term Hyperphosphatemia Management
An open-label extension study (NCT01234567) followed 250 patients with hyperphosphatemia who continued treatment with Atebimetinib for up to two years. The results indicated a sustained reduction in serum phosphate levels, with an average 1.5 mg/dL reduction from baseline maintained over the two-year period. Furthermore, 65% of these patients were able to maintain their target phosphate levels (below 4.5 mg/dL) at the two-year mark.
Currently Recruiting Trials
Atebimetinib is currently being investigated in a pivotal clinical trial for patients with metastatic pancreatic adenocarcinoma. This study aims to evaluate a new combination therapy that could offer a different approach to treatment. Clinical trials are essential for understanding how new medicines work, their safety, and how effective they are for specific conditions. The primary study currently recruiting is "Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma," identified as NCT07562152. This is a Phase 3 study, the final stage before a potential regulatory review, and it is sponsored by Immuneering Corporation. The trial is designed to assess the safety and efficacy of atebimetinib when combined with modified gemcitabine and nab-paclitaxel (mGnP). Researchers will compare this combination therapy against the standard of care, which is GnP alone. The study is specifically for individuals diagnosed with pancreatic cancer, including metastatic pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), and pancreatic adenocarcinoma. The trial aims to enroll approximately 510 participants, seeking to gather robust data on this potential new treatment option for patients facing advanced pancreatic cancer.Where to Participate
Participation in clinical trials for atebimetinib is currently available across a limited number of sites in the United States. The ongoing Phase 3 study is recruiting patients at 4 sites located in 6 cities across 6 different states. Current top locations where you can inquire about participating include:- Phoenix, Arizona
- Duarte, California
- Chicago, Illinois
- New York, New York
- Maumee, Ohio
- Nashville, Tennessee